The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

The Cancer Drug Development Forum (CDDF) held a live webinar on “Clinical Research in Central and Eastern Europe, Realising the opportunities “ on Monday 12 February 2024 at 17:00 (CET) / 11:00 (EST). In this webinar, Susan Bhatti (Merck BV, NL), Mark Lawler (Queen’s University Belfast & CDDF), Wiktor Janicki (AstraZeneca, PL) provided interesting talks followed by a Q&A discussion moderated by Axel Glasmacher (CDDF). Here are key takeaways from the webinar:


🔶[Susan Bhatti (Merck BV, NL): What do we need to change to have smarter, faster, more patient centered trials in Europe]

  • Clinical trials are an important option for patients in Europe to potentially benefit from the latest advances in clinical research
  • The number of clinical trials in the EU has been steadily decreasing since 2020 and the downward trend was even more pronounced in 2023
  • To reverse this trend a multi-stakeholder effort is needed by academia, regulators, patients and industry to bring smarter, faster, more patient centric trials to Europe

🔶[Mark Lawler (Queen’s University Belfast & CDDF): Deploying data to understand cancer research challenges and opportunities in Central and Eastern Europe]

  • Data intelligence is key to understanding opportunities and challenges to clinical cancer research in Central and Eastern Europe (CEE)
  • We need to look at cancer clinical research in the context of the COVID 19 pandemic, the war in Ukraine and the global economic downturn
  • There is an urgent need to mitigate these impacts, particularly given the primary role of cancer clinical trials in Ukraine and Russia on the CEE region

🔶[Wiktor Janicki (AstraZeneca, PL): Does Poland have the potential to become the next cancer research hub?]

  • Poland and more broadly CEE is an attractive place for cancer research as evidenced by productivity and quality metrics
  • The development of the AZ global R&D hub in Poland can act as an inspiration for similar industry initiatives
  • There is significant untapped research potential in the region given its human capital, site development and recognition of the importance of clinical trials by the governments


🔶Watch the webinar recording HERE
🔶View the key takeaway video HERE

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70